Compounds > a-922500
Page last updated: 2024-11-13

a-922500

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID24768261
CHEMBL ID430405
CHEBI ID191423
SCHEMBL ID2742723
MeSH IDM0538344

Synonyms (36)

Synonym
HY-10038
bdbm20716
(1r,2r)-2-[(4-{4-[(phenylcarbamoyl)amino]phenyl}phenyl)carbonyl]cyclopentane-1-carboxylic acid
CHEMBL430405
CHEBI:191423
a 922500 ,
(1r,2r)-2-[4-[4-(phenylcarbamoylamino)phenyl]benzoyl]cyclopentane-1-carboxylic acid
959122-11-3
BCP9000206
a922500 ,
CS-0308
S2674
AKOS022179837
MLS006011108
smr004702890
a-922500
unii-44698m475x
44698m475x ,
cyclopentanecarboxylic acid, 2-((4'-(((phenylamino)carbonyl)amino)(1,1'-biphenyl)-4-yl)carbonyl)-, (1r,2r)-
J-500277
SCHEMBL2742723
(1r,2r)-2-[[4'-[[phenylamino)carbonyl]amino] [1,1'-biphenyl]-4-yl]carbonyl]cyclopentanecarboxylic acid
dgat-1 inhibitor 4a
(1r,2r)-2-(4'-(3-phenylureido)-[1,1'-biphenyl]-4-carbonyl)cyclopentanecarboxylic acid
(1r,2r)-2-(4'-(3-phenylureido)-[1,1'-biphenyl]-4-carbonyl)cyclopentane-1-carboxylic acid
DTXSID80242027
BOZRFEQDOFSZBV-DHIUTWEWSA-N ,
(1r,2r)-2-({4'-[(anilinocarbonyl)amino]-1,1'-biphenyl-4-yl}carbonyl)cyclopentanecarboxylic acid
EX-A3976
cid 24768261
CCG-268982
Q27258710
dgat-1inhibitor 4a
AS-76626
AC-36900
E98865

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice."( Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
Beno, DW; Brodjian, S; Brune, ME; Collins, CA; Dayton, BD; Diaz, GJ; Droz, B; Engstrom, KM; Falls, HD; Freeman, J; Fry, D; Gao, J; Grihalde, N; Iyengar, RR; Judd, AS; Kym, PR; Lau, YY; Lynch, JK; Marsh, KC; Mulhern, MM; Ravn, MM; Reilly, RM; Sham, H; Souers, AJ; Su, Z; Voorbach, M; Wagaw, SH; Wang, X; Zhao, G, 2008)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Diacylglycerol O-acyltransferase 1Homo sapiens (human)IC50 (µMol)0.01430.00050.04300.4300AID1461832; AID1798006; AID312792; AID621060; AID621085
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.02000.00020.660310.0000AID621060
Diacylglycerol O-acyltransferase 1Mus musculus (house mouse)IC50 (µMol)0.01830.00110.01400.0240AID1798006; AID312793
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
triglyceride biosynthetic processDiacylglycerol O-acyltransferase 1Homo sapiens (human)
monoacylglycerol biosynthetic processDiacylglycerol O-acyltransferase 1Homo sapiens (human)
triglyceride metabolic processDiacylglycerol O-acyltransferase 1Homo sapiens (human)
triglyceride biosynthetic processDiacylglycerol O-acyltransferase 1Homo sapiens (human)
lipid storageDiacylglycerol O-acyltransferase 1Homo sapiens (human)
very-low-density lipoprotein particle assemblyDiacylglycerol O-acyltransferase 1Homo sapiens (human)
long-chain fatty-acyl-CoA metabolic processDiacylglycerol O-acyltransferase 1Homo sapiens (human)
retinol metabolic processDiacylglycerol O-acyltransferase 1Homo sapiens (human)
diacylglycerol metabolic processDiacylglycerol O-acyltransferase 1Homo sapiens (human)
fatty acid homeostasisDiacylglycerol O-acyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
2-acylglycerol O-acyltransferase activityDiacylglycerol O-acyltransferase 1Homo sapiens (human)
diacylglycerol O-acyltransferase activityDiacylglycerol O-acyltransferase 1Homo sapiens (human)
protein bindingDiacylglycerol O-acyltransferase 1Homo sapiens (human)
acyltransferase activityDiacylglycerol O-acyltransferase 1Homo sapiens (human)
identical protein bindingDiacylglycerol O-acyltransferase 1Homo sapiens (human)
retinol O-fatty-acyltransferase activityDiacylglycerol O-acyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneDiacylglycerol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneDiacylglycerol O-acyltransferase 1Homo sapiens (human)
plasma membraneDiacylglycerol O-acyltransferase 1Homo sapiens (human)
membraneDiacylglycerol O-acyltransferase 1Homo sapiens (human)
specific granule membraneDiacylglycerol O-acyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (49)

Assay IDTitleYearJournalArticle
AID312818Decrease in liver triglyceride level in DIO C57BL/6J mouse at 3 mg/kg, po after 28 days2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID1461830Inhibition of recombinant full length human DGAT1 expressed in Sf9 insect cells using 1,2-didecanoyl-sn-glycerol as substrate at 1 uM after 60 mins in presence of palmitoyl-1-14C coenzyme A by scintillation counting2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.
AID312802AUC in rat at 5 mg/kg, iv2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312822Reduction of chylomicron-derived serum triglyceride level in acute lipid challenged DIO C57BL/6J mouse at 0.3 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312810AUC in dog at 2.5 mg/kg, iv2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID621060Inhibition of human DGAT1 assessed as formation of [14C]-triglyceride using [14C]oleoyl-CoA by liquid scintillation counting2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
AID312794Inhibition of mouse DGAT22008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312793Inhibition of mouse recombinant DGAT1 expressed in Sf9 cells2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312795Inhibition of human ACAT12008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID645241Cytotoxicity against monkey MA104 cells after 24 hrs2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID312809Volume of distribution at terminal phase in dog at 2.5 mg/kg, iv2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312797Half life in DIO mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID1461832Inhibition of recombinant full length human DGAT1 expressed in Sf9 insect cells using 1,2-didecanoyl-sn-glycerol as substrate after 60 mins in presence of palmitoyl-1-14C coenzyme A by scintillation counting2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.
AID312801Volume of distribution at terminal phase in rat at 5 mg/kg, iv2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID1461868Reduction in oleic acid-induced triglyceride generation in human HepG2 cells preincubated for 2 hrs followed oleic acid addition measured after 48 hrs by Oil Red O staining-based assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.
AID312823Reduction of chylomicron-derived serum triglyceride level in acute lipid challenged DIO C57BL/6J mouse at 3 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID1461831Inhibition of recombinant full length human DGAT1 expressed in Sf9 insect cells using 1,2-didecanoyl-sn-glycerol as substrate at 0.1 uM after 60 mins in presence of palmitoyl-1-14C coenzyme A by scintillation counting2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.
AID312792Inhibition of human recombinant DGAT1 expressed in Sf9 cells2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID1461865Reduction of olive oil-induced acute high-serum triglyceride level in C57/KSJ mouse at 10 mg/kg, po pretreated for 1 hr followed by olive oil challenge measured after 2 hrs post olive oil challenge2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.
AID312807Oral bioavailability in rat at 5 mg/kg2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312824Reduction of chylomicron-derived serum triglyceride level in acute lipid challenged DIO C57BL/6J mouse at 30 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312799AUC in DIO mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID621085Inhibition of human DGAT1 expressed in Sf9 cells assessed as formation of didecanoylglycerol product after 1 hr using 14C-decanoyl-CoA by beta scintillation counter2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
AID1461867Reduction in oleic acid-induced triglyceride generation in human Caco-2 cells preincubated for 2 hrs followed oleic acid addition measured after 48 hrs by Oil Red O staining-based assay2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.
AID312812Half life in dog at 2.5 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312796Inhibition of human ACAT22008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312798Cmax in DIO mouse at 10 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312820Cmax in C57BL/6J mouse at 3 mg/kg, po after 1 hr2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312804Half life in rat at 5 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID1461869Reduction of olive oil-induced acute high-serum triglyceride level in C57/KSJ mouse at 1 to 10 mg/kg,po pretreated for 2 hrs followed by olive oil challenge post dose2017Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17
Discovery of a low-systemic-exposure DGAT-1 inhibitor with a picolinoylpyrrolidine-2-carboxylic acid moiety.
AID312821Drug level in C57BL/6J mouse at 3 mg/kg, po after 18 hrs2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID621062Antiobesity activity in fasted Swiss mouse assessed as reduction of triglyceride level at 10 mg/kg, po administered 1 hr before olive oil administration measured after 4 hrs relative to control2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
AID312800Half life in rat at 5 mg/kg, iv2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312816Decrease in body weight in DIO C57BL/6J mouse at 10 mg/kg, po qd after 14 days2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID621086Antiobesity activity in diet-induced obese C57bl/J6 mouse model assessed as reduction of triglyceride level at 10 mg/kg, po qd for 7 days relative to control2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
AID312811Plasma clearance in dog at 2.5 mg/kg, iv2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312819Increase in liver triglyceride level in DIO C57BL/6J mouse at 3 mg/kg, po after 28 days2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID645239Antiviral activity against Rotavirus SA11 in MA104 cells assessed as inhibition of viral replication after 24 hrs by immunofluorescent assay and Western blotting analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID312814AUC in dog at 2.5 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312803Plasma clearance in rat at 5 mg/kg, iv2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312813Cmax in dog at 2.5 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312817Decrease in body weight in DIO C57BL/6J mouse at 3 mg/kg, po bid after 7 days2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312815Oral bioavailability in dog at 2.5 mg/kg2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID621084Solubility of compound at pH 7.42011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Exploration of pyridine containing heteroaryl analogs of biaryl ureas as DGAT1 inhibitors.
AID312808Half life in dog at 2.5 mg/kg, iv2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312806AUC in rat at 5 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID312805Cmax in rat at 5 mg/kg, po2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1798006In Vitro FlashPlate Assay from Article 10.1021/jm7013887: \\Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.\\2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.91 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
troglitazone
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.		2.0710chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
cetaben
[no description available]		2.0710
betulinic acid
[no description available]		2.0710hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
pd 128042
PD 128042: structure given in first source		2.0710anilide
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		2.0710epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
triacsin c
triacsin C: from Streptomyces No. 1228; structure given in first source; an acyl-CoA synthetase antagonist. triacsin C : A nitroso compound that is N-undecylnitrous hydrazide carrying double bonds at positions 1,2,4, and 7. It is a long-chain fatty acyl CoA synthetase inhibitor and interferes with lipid metabolism by inhibiting the de novo synthesis of glycerolipids and cholesterol esters.		2.0710hydrazone;
nitroso compound;
olefinic compound		antimalarial;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
vasodilator agent
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid: an anorectic fatty acid synthase inhibitor; structure in first source. (2R,3S)-C75 : A 4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid that has 2R,3S-configuration.		2.07104-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid;
gamma-lactone
pradigastat
[no description available]		2.1510
ConditionIndicatedRelationship StrengthStudiesTrials
Weight Reduction
[description not available]		02.0410
Weight Loss
Decrease in existing BODY WEIGHT.		02.0410
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.0610
Rotavirus Infections
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.		02.0710